Biopharma ESG Risk: Introducing Our Capsule System for Assessing U.S. Drug Pricing Risk With ICER Cost-Effectiveness Benchmark
Biopharma ESG Risk: Introducing Our Capsule System for Assessing U.S. Drug Pricing Risk With ICER Cost-Effectiveness Benchmark
Drug pricing is complex. Few people know the exact net prices drug wholesalers, pharmacies, pharmacy benefit managers, managed-care organizations, governments, and patients pay once all rebates and discounts are tallied. To simplify the analysis of a company’s drug pricing practices, Morningstar is introducing a capsule numbering system that categorizes companies into one of five buckets.
What's Inside
What's Inside
- What capsules we’ve assigned to 18 of the largest biopharma firms in Morningstar’s coverage
- How policy restructuring, aggressive private-payer actions, or ESG pressure on the biopharma industry might impact individual firms
- How the use of capsules will be embedded into the Sustainalytics ESG Risk Rating analysis and what this could mean moving forward